Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?
NCT ID: NCT03142139
Last Updated: 2017-05-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
1027559 participants
Study Classification
OBSERVATIONAL
Study Start Date
1997-01-01
Study Completion Date
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards vaccine unrelated pathogens, resulting in excess mortality(Aaby, Kollmann, \& Benn, 2014).
A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced risk of atopic dermatitis (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016).
This register based observational study aims to extend the existing knowledge on non-specific effects of non-live vaccines by testing the above finding, that delayed vaccination with Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b (DTaP-IPV-Hib) is associated with lower risk of developing atopic dermatitis before 1 year of age in the Danish birth cohorts from 1997-2012.
A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced risk of atopic dermatitis (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016).
This register based observational study aims to extend the existing knowledge on non-specific effects of non-live vaccines by testing the above finding, that delayed vaccination with Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b (DTaP-IPV-Hib) is associated with lower risk of developing atopic dermatitis before 1 year of age in the Danish birth cohorts from 1997-2012.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants
NCT02477995
Pertussis
COMPLETED
PHASE3
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
NCT01346293
Tetanus
Diphtheria
Pertussis
+2 more
COMPLETED
PHASE3
Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
NCT06344065
Healthy Volunteers
RECRUITING
PHASE3
Impact of Vaccination on Th2 Immunity in Infancy
NCT02213341
Food Hypersensitivity
TERMINATED
Tdap Vaccination for Infant Caregivers
NCT01233401
Pertussis
Vaccination
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called non-specific effects with the potential to affect resistance towards vaccine unrelated pathogens, resulting in excess mortality and morbidity(Aaby et al., 2014). These immunomodifying effects may affect development of atopic dermatitis through increased immunological sensitivity(Nilsson, Gruber, Granstrom, Bjorksten, \& Kjellman, 1998). A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced eczema (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016). The present study aims to test the above finding and investigate the effect of timeliness of vaccination with DTaP-IPV-Hib (with or without PCV) on development of atopic dermatitis before 1 year of age among Danish children born between 1997 and 2012. From 1997 to 2012 children in Denmark were scheduled to receive the 1st, 2nd, and 3rd dose of DTaP-IPV-Hib at 3, 5, and 12 months respectively.
Primary investigation:
Research question 1.a Is delayed vaccination with the first dose of DTaP-IPV-Hib (vaccination at or after 4 months of age) associated with a reduced risk of development of atopic dermatitis from 4 months and until but not including 12 months of age compared with receiving the first dose of DTaP-IPV-Hib before 4 months of age?
Secondary investigations:
Research question 1.b Among children with a timely 1st dose of DTaP-IPV-Hib (vaccination before 4 months of age), is delayed vaccination with the second dose of DTaP-IPV-Hib (vaccination at or after 6 months of age) associated with a reduced risk of development of atopic dermatitis from 6 months and until but not including 12 months of age compared with receiving the second dose of DTaP-IPV-Hib before 6 months of age?
Research question 2. Is receipt of DTaP-IPV-Hib associated with development of atopic dermatitis from 3 months and until but not including 8 months of age compared with being unvaccinated?
Data assessment Information on development of atopic dermatitis and vaccination status is assessed at baseline (which is 4 months of age (research question 1.a.),6 months of age (research question 1.b.) and 3 months of age (research question 2.)) and through follow up (until 1 year of age). Confounder information is assessed at 3 months of age for all analyses.
Development of atopic dermatitis is assessed according to an algorithm described in detail under "9. Outcome measures", which uses information on prescriptions and hospitalizations up until one year after the last age of outcome assessment (1 year of age in this study) to confirm a case. Children must therefore be alive and living in Denmark until 2 years of age representative of age at end of follow-up plus 1 year.
The Danish national registers contains individual-level information on a broad range of health and social factors. Every child born in Denmark receives a unique personal identification number (ID) at birth, which follows the individual through life. Using the ID it is possible to link information from the different registers at an individual level.
Confounders:
The investigators will seek to retain information on potential confounders from the Danish registers. Potential confounders will be assessed at 3 months of age and included in the adjusted analyses.
Information on sex, season of birth, death, emigration, parental identity, sibling's identity and exact address will be obtained from the Danish Civil Registration System. The investigators will use information on parental identity to link every child to its parents and obtain information on parents' origin of birth, single parenthood and the number of children in the household. The investigators will furthermore derive information on population density based on information on the municipality in which the child lives. Information on parental and sibling's identity will be used to link information on family history of atopic dermatitis to the child. Atopic dermatitis is categorized according to the algorithm described in detail under "9. Outcome measures".
The variables; caesarean section, preterm birth, birthweight, and maternal smoking during pregnancy is obtained from the Danish Medical Birth Register, which contains information on all live and stillbirths in Denmark. Antibiotic use is recorded in the Danish National Prescription Register. Information on chronic disease is obtained from in the Danish national patient registry. Household income is obtained from the Danish registers on personal income and transfer payment.
Maternal highest education is obtained from the Danish education registers.
The dataset is expected to contain close to complete information on confounders. Hence, it is expected that children with missing confounder information constitute an ignorable proportion of the complete study population, wherefore the investigators aim to conduct complete case analyses only.
Statistical model for research question 1.a +1.b; investigation of the effect of timing of vaccination.
For investigation of the effect of timing of the first and second dose of DTaP-IPV-Hib with or without PCV, a Binary regression model will be used to estimate the adjusted relative risk of developing atopic dermatitis from baseline (age for categorized timely vaccination) until one year of age, among delayed vaccinated compared to timely vaccinated children. The analysis will include all abovementioned potential confounders. Absolute risk differences will be reported if relevant.
Intended subgroup and sensitivity analysis for the primary investigation (research question 1.a)
The following presents a priory identified relevant subgroup and sensitivity analyses. If relevant, additional analysis will be included with the aim to pursue potential tendencies revealed in the data analysis.
1. Sex differential effect Data will be analyzed for effect modification by sex because of evidence of sex-differential non-specific effects of vaccines (Aaby et al., 2014) and also sex-differential atopic sensitization associated with delayed vaccination (Kiraly et al., 2016).
2. Further subgroup analyses
* Effect modification by PCV vaccination. PCV was enrolled into the Danish vaccination schedule during the years of this investigation. Hence, it will be investigated if potential NSEs of DTaP-IPV-Hib vary according to receipt of PCV.
* Exploratory analysis of effect modification.
* Subgroup analysis, which only includes first born children; Parents of children with older siblings may be more familiar with AD, which may result in a less frequent health care seeking behavior. Parents of children with older siblings, who have had AD themselves, may further have prescription medicines in the home from treatment of prior cases of AD among the siblings. Hence, cases of AD categorized based on disease specific prescriptions may be misclassified if the parents do not get a new prescription for that child.
3. Sensitivity analyses
* Sensitivity analysis to investigate if the results are affected by inclusion of children with no DTaP-IPV-Hib before 1 year of age.
* Investigation of reverse causation: A Cox regression will be conducted to investigate if presence of atopic dermatitis is associated with subsequent delayed vaccination.
* Inclusion of negative control outcome/exposure; In similar studies, it has been suspected that there may be a risk of ascertainment bias, whereby parents of children who are delayed vaccinated, represent parents with a general lower health care seeking behavior, which could result in lower levels of AD diagnosis among their children. In order to accommodate this potential unmeasured confounder, the investigators will seek to identify a relevant negative control exposure or outcome, which will help indicate the strength of a potential interference from this unmeasured confounder.
Statistical model for investigation of research question 2; investigation of the effect of being vaccinated with DTaP-IPV-Hib with or without PCV compared with being non-vaccinated.
For investigation of the effect of being vaccinated with DTaP-IPV-Hib compared with being non-vaccinated a Cox proportional hazards regression with age as the underlying time will be used to estimate the adjusted HR of developing atopic dermatitis among children vaccinated with DTaP-IPV-Hib compared with unvaccinated children. Vaccination status will be assessed from time of scheduled vaccination (3 months of age) and set as a time dependent variable with the categories unvaccinated and vaccinated.
As vaccination status is included as a time dependent variable, the group of unvaccinated children will inherently become smaller with time as they get vaccinated. In order to assure sufficient group sizes, children will only be followed until 8 months of age.
The model will include all identified potential confounding factors listed above. All co-variates will be included as fixed variables and assessed at baseline (3 months of age).
Proportional hazard assumption will be examined.
Sensitivity analysis for the Cox regression
\- Delayed diagnosis; Atopic dermatitis does not become apparent until the child has scratched the affected skin. Furthermore, it may take weeks to months before the parents become aware that this is not something which is passing, and bring the child to a doctor. Therefore, it is very likely that actual onset of AD is weeks/months prior to date of diagnosis by the healthcare professionals or receipt of disease specific prescriptions. Due to this delay, there is a risk of differential misclassification, whereby cases of AD may be falsely ascribed to the vaccinated exposure group. A sensitivity analysis will account for this delay by setting the date for onset of AD prior to onset according to the AD algorithm. Primary health care facilities will be contacted in order to gain expert insight on approximate delay from onset of symptoms to receipt of prescription medicines or referral to a hospital.
Primary investigation:
Research question 1.a Is delayed vaccination with the first dose of DTaP-IPV-Hib (vaccination at or after 4 months of age) associated with a reduced risk of development of atopic dermatitis from 4 months and until but not including 12 months of age compared with receiving the first dose of DTaP-IPV-Hib before 4 months of age?
Secondary investigations:
Research question 1.b Among children with a timely 1st dose of DTaP-IPV-Hib (vaccination before 4 months of age), is delayed vaccination with the second dose of DTaP-IPV-Hib (vaccination at or after 6 months of age) associated with a reduced risk of development of atopic dermatitis from 6 months and until but not including 12 months of age compared with receiving the second dose of DTaP-IPV-Hib before 6 months of age?
Research question 2. Is receipt of DTaP-IPV-Hib associated with development of atopic dermatitis from 3 months and until but not including 8 months of age compared with being unvaccinated?
Data assessment Information on development of atopic dermatitis and vaccination status is assessed at baseline (which is 4 months of age (research question 1.a.),6 months of age (research question 1.b.) and 3 months of age (research question 2.)) and through follow up (until 1 year of age). Confounder information is assessed at 3 months of age for all analyses.
Development of atopic dermatitis is assessed according to an algorithm described in detail under "9. Outcome measures", which uses information on prescriptions and hospitalizations up until one year after the last age of outcome assessment (1 year of age in this study) to confirm a case. Children must therefore be alive and living in Denmark until 2 years of age representative of age at end of follow-up plus 1 year.
The Danish national registers contains individual-level information on a broad range of health and social factors. Every child born in Denmark receives a unique personal identification number (ID) at birth, which follows the individual through life. Using the ID it is possible to link information from the different registers at an individual level.
Confounders:
The investigators will seek to retain information on potential confounders from the Danish registers. Potential confounders will be assessed at 3 months of age and included in the adjusted analyses.
Information on sex, season of birth, death, emigration, parental identity, sibling's identity and exact address will be obtained from the Danish Civil Registration System. The investigators will use information on parental identity to link every child to its parents and obtain information on parents' origin of birth, single parenthood and the number of children in the household. The investigators will furthermore derive information on population density based on information on the municipality in which the child lives. Information on parental and sibling's identity will be used to link information on family history of atopic dermatitis to the child. Atopic dermatitis is categorized according to the algorithm described in detail under "9. Outcome measures".
The variables; caesarean section, preterm birth, birthweight, and maternal smoking during pregnancy is obtained from the Danish Medical Birth Register, which contains information on all live and stillbirths in Denmark. Antibiotic use is recorded in the Danish National Prescription Register. Information on chronic disease is obtained from in the Danish national patient registry. Household income is obtained from the Danish registers on personal income and transfer payment.
Maternal highest education is obtained from the Danish education registers.
The dataset is expected to contain close to complete information on confounders. Hence, it is expected that children with missing confounder information constitute an ignorable proportion of the complete study population, wherefore the investigators aim to conduct complete case analyses only.
Statistical model for research question 1.a +1.b; investigation of the effect of timing of vaccination.
For investigation of the effect of timing of the first and second dose of DTaP-IPV-Hib with or without PCV, a Binary regression model will be used to estimate the adjusted relative risk of developing atopic dermatitis from baseline (age for categorized timely vaccination) until one year of age, among delayed vaccinated compared to timely vaccinated children. The analysis will include all abovementioned potential confounders. Absolute risk differences will be reported if relevant.
Intended subgroup and sensitivity analysis for the primary investigation (research question 1.a)
The following presents a priory identified relevant subgroup and sensitivity analyses. If relevant, additional analysis will be included with the aim to pursue potential tendencies revealed in the data analysis.
1. Sex differential effect Data will be analyzed for effect modification by sex because of evidence of sex-differential non-specific effects of vaccines (Aaby et al., 2014) and also sex-differential atopic sensitization associated with delayed vaccination (Kiraly et al., 2016).
2. Further subgroup analyses
* Effect modification by PCV vaccination. PCV was enrolled into the Danish vaccination schedule during the years of this investigation. Hence, it will be investigated if potential NSEs of DTaP-IPV-Hib vary according to receipt of PCV.
* Exploratory analysis of effect modification.
* Subgroup analysis, which only includes first born children; Parents of children with older siblings may be more familiar with AD, which may result in a less frequent health care seeking behavior. Parents of children with older siblings, who have had AD themselves, may further have prescription medicines in the home from treatment of prior cases of AD among the siblings. Hence, cases of AD categorized based on disease specific prescriptions may be misclassified if the parents do not get a new prescription for that child.
3. Sensitivity analyses
* Sensitivity analysis to investigate if the results are affected by inclusion of children with no DTaP-IPV-Hib before 1 year of age.
* Investigation of reverse causation: A Cox regression will be conducted to investigate if presence of atopic dermatitis is associated with subsequent delayed vaccination.
* Inclusion of negative control outcome/exposure; In similar studies, it has been suspected that there may be a risk of ascertainment bias, whereby parents of children who are delayed vaccinated, represent parents with a general lower health care seeking behavior, which could result in lower levels of AD diagnosis among their children. In order to accommodate this potential unmeasured confounder, the investigators will seek to identify a relevant negative control exposure or outcome, which will help indicate the strength of a potential interference from this unmeasured confounder.
Statistical model for investigation of research question 2; investigation of the effect of being vaccinated with DTaP-IPV-Hib with or without PCV compared with being non-vaccinated.
For investigation of the effect of being vaccinated with DTaP-IPV-Hib compared with being non-vaccinated a Cox proportional hazards regression with age as the underlying time will be used to estimate the adjusted HR of developing atopic dermatitis among children vaccinated with DTaP-IPV-Hib compared with unvaccinated children. Vaccination status will be assessed from time of scheduled vaccination (3 months of age) and set as a time dependent variable with the categories unvaccinated and vaccinated.
As vaccination status is included as a time dependent variable, the group of unvaccinated children will inherently become smaller with time as they get vaccinated. In order to assure sufficient group sizes, children will only be followed until 8 months of age.
The model will include all identified potential confounding factors listed above. All co-variates will be included as fixed variables and assessed at baseline (3 months of age).
Proportional hazard assumption will be examined.
Sensitivity analysis for the Cox regression
\- Delayed diagnosis; Atopic dermatitis does not become apparent until the child has scratched the affected skin. Furthermore, it may take weeks to months before the parents become aware that this is not something which is passing, and bring the child to a doctor. Therefore, it is very likely that actual onset of AD is weeks/months prior to date of diagnosis by the healthcare professionals or receipt of disease specific prescriptions. Due to this delay, there is a risk of differential misclassification, whereby cases of AD may be falsely ascribed to the vaccinated exposure group. A sensitivity analysis will account for this delay by setting the date for onset of AD prior to onset according to the AD algorithm. Primary health care facilities will be contacted in order to gain expert insight on approximate delay from onset of symptoms to receipt of prescription medicines or referral to a hospital.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atopic Dermatitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Danish Birth Cohorts 1997-2012
RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib
RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis.
RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
Intervention Type
BIOLOGICAL
Children will be categorized as "timely vaccinated" if they receive the 1st dose within the month of scheduled vaccination:
* "timely vaccinated": received 1st dose of DTaP-IPV-Hib before 4 months of age
* "delayed vaccinated": did not receive the first dose of DTaP-IPV-Hib before 4 months of age.
RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib
Intervention Type
BIOLOGICAL
Children will be categorized as "timely vaccinated" if they receive the 2nd dose within the month of scheduled vaccination:
* "timely vaccinated": received 2nd dose of DTaP-IPV-Hib before 6 months of age
* "delayed vaccinated": did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age.
RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
Intervention Type
BIOLOGICAL
• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as "unvaccinated" until date of vaccination where they will shift exposure group to "vaccinated".
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
Children will be categorized as "timely vaccinated" if they receive the 1st dose within the month of scheduled vaccination:
* "timely vaccinated": received 1st dose of DTaP-IPV-Hib before 4 months of age
* "delayed vaccinated": did not receive the first dose of DTaP-IPV-Hib before 4 months of age.
Intervention Type
BIOLOGICAL
RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib
Children will be categorized as "timely vaccinated" if they receive the 2nd dose within the month of scheduled vaccination:
* "timely vaccinated": received 2nd dose of DTaP-IPV-Hib before 6 months of age
* "delayed vaccinated": did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age.
Intervention Type
BIOLOGICAL
RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as "unvaccinated" until date of vaccination where they will shift exposure group to "vaccinated".
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Born in Denmark between between 1 January 1997 - 31 December 2012
Exclusion Criteria
* Do not receive 1st dose of DTaP-IPV-Hib before 1 year of age
* Died before 24 months of age
* Migrate before 24 months of age
* Receive any vaccines other than DTaP-IPV-Hib, with or without PCV before 12 months of age
* Develop Atopic Dermatitis prior to baseline
* Have missing confounder information
* Died before 24 months of age
* Migrate before 24 months of age
* Receive any vaccines other than DTaP-IPV-Hib, with or without PCV before 12 months of age
* Develop Atopic Dermatitis prior to baseline
* Have missing confounder information
Minimum Eligible Age
24 Months
Maximum Eligible Age
24 Months
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Murdoch Childrens Research Institute
OTHER
Sponsor Role
collaborator
Bandim Health Project
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Signe Sørup, PhD
Role: PRINCIPAL_INVESTIGATOR
CVIVA, Bandim Health Project
References
Explore related publications, articles, or registry entries linked to this study.
Larsson M, Hagerhed-Engman L, Sigsgaard T, Janson S, Sundell J, Bornehag CG. Incidence rates of asthma, rhinitis and eczema symptoms and influential factors in young children in Sweden. Acta Paediatr. 2008 Sep;97(9):1210-5. doi: 10.1111/j.1651-2227.2008.00910.x.
Reference Type
BACKGROUND
Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011 Jul;39(7 Suppl):38-41. doi: 10.1177/1403494810394717.
Reference Type
BACKGROUND
Kiraly N, Koplin JJ, Crawford NW, Bannister S, Flanagan KL, Holt PG, Gurrin LC, Lowe AJ, Tang ML, Wake M, Ponsonby AL, Dharmage SC, Allen KJ. Timing of routine infant vaccinations and risk of food allergy and eczema at one year of age. Allergy. 2016 Apr;71(4):541-9. doi: 10.1111/all.12830. Epub 2016 Feb 8.
Reference Type
BACKGROUND
Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011 Jul;39(7 Suppl):30-3. doi: 10.1177/1403494811401482.
Reference Type
BACKGROUND
Nilsson L, Gruber C, Granstrom M, Bjorksten B, Kjellman NI. Pertussis IgE and atopic disease. Allergy. 1998 Dec;53(12):1195-201. doi: 10.1111/j.1398-9995.1998.tb03841.x.
Reference Type
BACKGROUND
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015 Nov 17;7:449-90. doi: 10.2147/CLEP.S91125. eCollection 2015.
Reference Type
BACKGROUND
Sorup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014 Feb 26;311(8):826-35. doi: 10.1001/jama.2014.470.
Reference Type
BACKGROUND
Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol. 2014 Oct;15(10):895-9. doi: 10.1038/ni.2961.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DTaP-Delay
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
NCT06184542
RECRUITING
PHASE1
Duration of Protection: GSK DTaP Vaccines
NCT02447978
COMPLETED
Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers
NCT07213089
COMPLETED
PHASE2/PHASE3
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
NCT07203755
RECRUITING
PHASE1
Study of Adacel® Vaccine Administered to Persons 10 Years of Age
NCT01311557
COMPLETED
PHASE4
Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children
NCT05870618
UNKNOWN
PHASE4
A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
NCT05951725
ACTIVE_NOT_RECRUITING
PHASE3
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
NCT00662870
COMPLETED
PHASE3
Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )
NCT05870631
UNKNOWN
PHASE4
Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .
NCT04099303
COMPLETED
PHASE1
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
NCT05091619
ACTIVE_NOT_RECRUITING
PHASE3
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
NCT00304265
COMPLETED
PHASE4
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
NCT00467519
COMPLETED
PHASE3
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
NCT07112144
RECRUITING
PHASE3
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
NCT00004799
COMPLETED
PHASE3
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
NCT01546909
COMPLETED
PHASE4
Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine
NCT06857370
ACTIVE_NOT_RECRUITING
PHASE3
Development and Testing of ADEPT: A Parent Decision Support for Childhood Vaccinations
NCT04496453
COMPLETED
NA
Pertussis Vaccine in Healthy Pregnant Women
NCT00707148
COMPLETED
PHASE1
Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa
NCT04300192
COMPLETED
PHASE4
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058
NCT00548171
COMPLETED
PHASE4
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
NCT01267058
COMPLETED
PHASE3
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.
NCT00263679
COMPLETED
PHASE3
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
NCT06056050
ACTIVE_NOT_RECRUITING
PHASE1